• In July 2023, Thermo Fisher Scientific Inc. (US) collaborated with the national minority quality forum (NMQF), an independent non-profit organization dedicated to research and education. Through NMQF's Alliance for Representative Clinical Trials (ARC), this partnership aims to enhance the participation of historically underserved patient groups in clinical research.

• In April 2023, Almac Group (UK) launched the IXRS®3 Partnership Network, aimed at expediting the development and implementation of advanced eClinical solutions for biopharmaceutical sponsors.

• In March 2023, Icon Pic (Ireland) formed a strategic partnership with LEO Pharma (Denmark) with a focus on improving LEO Pharma's clinical trial operations. This collaboration emphasizes patient-centricity and cost-efficiency to strengthen LEO Pharma's clinical research endeavors.

• In August 2022, Marken (US) acquired Bomi Group to bolster its presence in healthcare logistics. This acquisition aims to expand Marken's international footprint and enhance its cold chain capabilities in key European and Latin American markets.

In this report, the Global Clinical Trial Supplies Market has been segmented by Clinical Phase, Product/Service, End Use, Therapeutic Use, and Geography.

Global Clinical Trial Supplies Market, Segmentation by Clinical Phase

The Global Clinical Trial Supplies Market has been segmented by Clinical Phase into Phase I, Phase II, Phase III, and Others.

Phase I
Phase I trials account for approximately 15% of the clinical trial supplies market. These initial studies focus on evaluating the safety and pharmacokinetics of a new drug in a small group of healthy volunteers. The supply chain for Phase I trials is characterized by smaller batches, strict handling protocols, and fast turnaround times.

Phase II
Phase II represents around 25% of the market. These trials assess efficacy and side effects in a larger patient population, requiring increased volumes of investigational medicinal products (IMPs), placebo kits, and clinical packaging. Coordination becomes more complex, involving temperature control and multi-site distribution.

Phase III
Phase III trials dominate with nearly 50% market share. They involve thousands of participants across multiple geographies, making logistics highly demanding. Clinical trial supplies for Phase III must meet global regulatory standards, include secondary packaging, labeling, and require robust forecasting to manage trial timelines effectively.

Others
Other phases, including Phase IV and exploratory trials, contribute approximately 10% of the market. These studies often focus on post-marketing surveillance and real-world evidence collection, with customized supply strategies tailored to longer timelines and patient retention programs.

Global Clinical Trial Supplies Market, Segmentation by Product/Service

The Global Clinical Trial Supplies Market has been segmented by Product/Service into Manufacturing, Storage & Distribution (Cold chain based, Non-cold chain based), and Supply chain management.

Manufacturing
Manufacturing services account for about 35% of the global clinical trial supplies market. This segment includes the production of investigational drugs, comparators, and placebo formulations. With growing trial complexity and the rise of biologics, demand for GMP-compliant, flexible manufacturing capabilities is increasing to support Phase I–III studies.

Storage & Distribution
Storage & distribution is the largest segment, comprising nearly 40% of the market and includes both cold chain and non-cold chain services. Cold chain logistics, which represent about 25%, are vital for maintaining the integrity of temperature-sensitive products like vaccines, gene therapies, and biologics. Non-cold chain services, around 15%, focus on oral solids and other stable compounds. Both require secure warehousing, inventory tracking, and efficient global transport solutions.

Supply Chain Management
Supply chain management holds an estimated 25% share of the clinical trial supplies market. Services include clinical labeling, forecasting, returns, and regulatory documentation. With trials becoming more global and decentralized, efficient supply chain orchestration is essential to reduce delays, prevent wastage, and maintain compliance.

Global Clinical Trial Supplies Market, Segmentation by End Use

The Global Clinical Trial Supplies Market has been segmented by End Use into Pharmaceuticals, Biologics, Medical Devices, and Others.

Pharmaceuticals
Pharmaceutical companies lead the clinical trial supplies market, contributing roughly 45% of the total share. These organizations manage large-scale global trials across multiple therapeutic areas. As drug pipelines expand and decentralized trials become more common, pharma companies increasingly rely on advanced logistics, temperature control, and supply chain management solutions.

Biologics
Biologics account for about 30% of the market. This segment includes complex biologic products such as monoclonal antibodies, vaccines, and gene/cell therapies that require specialized storage, labeling, and cold chain logistics. The rise of precision medicine and the growth of immunotherapies are further accelerating demand in this segment.

Medical Devices
Medical devices make up nearly 15% of clinical trial supply needs. These include diagnostic tools, implantables, and wearable devices used in clinical studies. Trials involving devices require tailored logistics support, often including calibration, packaging, and compliance with device-specific regulatory standards.

Others
Other end uses represent around 10% of the market. This includes nutraceutical trials, digital therapeutics, and alternative therapies. While smaller in volume, these segments require compliance-focused logistics, timely delivery, and secure tracking systems for investigational supplies.

Global Clinical Trial Supplies Market, Segmentation by Therapeutic Use

The Global Clinical Trial Supplies Market has been segmented by Therapeutic Use into Oncology, CNS, Cardiovascular, Infectious disease, Metabolic disorders, and Others.

Oncology
Oncology dominates the clinical trial supplies market with a share of approximately 35%. The complexity of cancer therapies—including biologics, immunotherapies, and personalized treatments—drives demand for specialized storage, packaging, and cold chain logistics. Global expansion of oncology trials further intensifies the need for flexible, compliant supply chain operations.

Central Nervous System (CNS)
CNS-related trials represent around 20% of the market. These trials, which include studies on depression, schizophrenia, and neurodegenerative disorders, often require long-term patient follow-up and sensitive handling of placebo-controlled medications. Timely delivery and patient adherence are critical factors in this segment.

Cardiovascular
Cardiovascular trials contribute nearly 15% of clinical trial supply demand. They involve large-scale patient recruitment and multi-center trials, especially for hypertension, heart failure, and cholesterol management therapies. Logistics for cardiovascular trials must be robust, scalable, and regulatory-compliant.

Infectious Disease
Infectious disease studies hold about 12% of the market. The ongoing evolution of antiviral drugs, vaccines, and antimicrobial resistance research has created strong demand for adaptable and rapid-response clinical supply chains, particularly in outbreak and pandemic settings.

Metabolic Disorders
Metabolic disorder trials make up roughly 10% of the market. Diseases such as type 2 diabetes, obesity, and thyroid dysfunction are fueling clinical studies globally. These trials often require cold storage solutions, accurate labeling, and strong site coordination to support ongoing patient management.

Others
Other therapeutic areas account for approximately 8% of the market. These include dermatology, immunology, rare diseases, gastrointestinal disorders, and women’s health. Each requires highly customized supply services, regulatory alignment, and strong inventory tracking.

Global Clinical Trial Supplies Market, Segmentation by Geography

In this report, the Global Clinical Trial Supplies Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.

Global Clinical Trial Supplies Market Share (%), by Geographical Region, 2024

North America
North America leads the global clinical trial supplies market, capturing around 40% of the total share. The U.S. is a major contributor, with its extensive clinical research infrastructure, large sponsor base, and advanced logistics networks. Strict FDA regulations also drive high demand for compliant and efficient supply chain services.

Europe
Europe holds approximately 25% of the market, supported by mature trial hubs and well-established regulatory frameworks. The EU’s Clinical Trials Regulation (CTR) has streamlined cross-border supply processes, making the region ideal for multicenter trials. Key contributors include Germany, the UK, and France.

Asia Pacific
Asia Pacific represents around 20% of global share. Countries like China, India, and Japan are seeing a surge in clinical trials due to growing pharma outsourcing, low operational costs, and rapid patient recruitment. The region is emerging as a strategic location for both early- and late-phase trials.

Middle East & Africa
Middle East & Africa contribute close to 8% of the market. Increased focus on research collaborations, improved healthcare infrastructure, and clinical research investments—especially in the GCC region—are boosting regional growth in clinical supply demand.

Latin America
Latin America holds nearly 7% of the global market. The region is gaining prominence in clinical trial execution thanks to regulatory reforms, diverse patient pools, and expanding healthcare investment. Brazil and Mexico are leading contributors in this region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Clinical Trial Supplies Market. These factors include; Market Drivers, Restraints, and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers:

• Increasing Demand for Clinical Research
• Rising Prevalence of Chronic Diseases
• Expanding Pharmaceutical and Biotechnology Industries
• Advancements in Personalized Medicine

• Globalization of Clinical Trials -

  The ongoing globalization of clinical trials is a major driver for the clinical trial supplies market, as pharmaceutical and biotech companies expand studies across multiple regions to access larger and more diverse patient populations. Conducting trials globally enables faster patient recruitment, greater epidemiological diversity, and regulatory alignment for product approvals in key markets. However, this expansion requires a highly coordinated and efficient supply chain capable of managing cross-border logistics, customs compliance, multi-site distribution, and variable regulatory frameworks.

  As sponsors increasingly run trials across North America, Europe, Asia-Pacific, Latin America, and emerging markets, the need for flexible, scalable, and regionally compliant supply solutions becomes critical. This includes cold chain logistics, local sourcing, and the ability to respond rapidly to changing site demands. Globalization is also fueling demand for technology-enabled tools such as integrated inventory management, real-time shipment tracking, and predictive supply forecasting, all of which contribute to minimizing delays and ensuring uninterrupted trial execution across geographically dispersed locations.

Restraints:

• Data Security Concerns
• Supply Chain Disruptions
• Patient Recruitment and Retention

• Ethical and Regulatory Compliance - Ethical and regulatory compliance is a significant restraint in the global clinical trial supplies market, as strict guidelines govern the sourcing, distribution, labeling, and handling of investigational products across different regions. Regulatory bodies such as the FDA, EMA, MHRA, and local health authorities impose rigorous standards to ensure patient safety, data integrity, and trial transparency. Navigating these diverse and evolving compliance requirements often leads to increased complexity, extended approval timelines, and higher operational costs.

  Ensuring ethical conduct also involves compliance with protocols related to informed consent, adverse event reporting, and patient confidentiality, which require precise documentation and secure handling of trial materials. Any deviation from established guidelines can result in regulatory audits, product recalls, or trial delays, severely impacting both trial timelines and sponsor reputation. These challenges highlight the need for experienced supply chain partners and robust governance frameworks to manage compliance across multi-site, multinational clinical trials effectively.

Opportunities:

• Expansion of Precision Medicine
• Digital Transformation
• Collaborations and Partnerships
• Focus on Patient-Centricity

• Investment in Infrastructure - Rising investment in infrastructure presents a substantial opportunity for the global clinical trial supplies market. As clinical research expands globally, sponsors and service providers are prioritizing the development of advanced logistics infrastructure, including purpose-built depots, GMP-compliant packaging facilities, and cold chain distribution hubs. These improvements enhance supply chain reliability, reduce lead times, and enable better coordination of trial materials across regions, particularly in emerging markets where demand for clinical research is growing rapidly.

  Infrastructure development also supports the adoption of decentralized and hybrid trial models by enabling faster, more flexible supply delivery. Investments in real-time tracking systems, automated inventory management, and temperature-controlled storage allow organizations to maintain quality and compliance while adapting to dynamic trial needs. This transformation helps ensure product integrity and patient safety, both of which are critical to trial success.

  Increased funding is also flowing into the digitization of supply chains, with integrated platforms that connect sponsors, CROs, logistics providers, and trial sites for improved communication and visibility. These systems reduce the risk of disruptions, improve forecasting accuracy, and support proactive decision-making. As infrastructure becomes more resilient and technology-enabled, the clinical trial supply ecosystem is better equipped to scale with the growing complexity and globalization of research.

  Governments and private investors are also playing a role by supporting infrastructure projects in clinical research hubs and underrepresented regions. These strategic investments not only promote regional trial participation but also foster greater operational efficiency and market access. As infrastructure capacity improves, it will unlock new geographic opportunities and enhance the responsiveness and competitiveness of the global clinical trial supplies market.

Key players in Global Clinical Trial Supplies Market include:

• Movianto (U.S.)
• Sharp Services, LLC (U.S.)
• Thermo Fisher Scientific Inc.,(U.S.)
• Catalent, Inc (U.S.)
• PCI Pharma Services (U.S.)
• Almac Group (U.K.)
• PAREXEL International Corporation (U.S.)
• Bionical Emas (U.K.)
• Alium Medical Limited (U.K.)
• Myonex (U.K.)
• Clinigen Limited (U.K.)
• Ancillare, LP (U.S.)
• SIRO Clinpharm Private Limited (India)
• Clinigen Clinical Supplies Management (U.S.)
• Biocair (U.K.)

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis